3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with Hallervorden-Spatz Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barthel, H; Dietrich, J; Georgi, P; Hermann, W; Reuter, M; Wagner, A | 2 |
2 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Hallervorden-Spatz Disease
| Article | Year |
|---|---|
Diagnosis of Hallervorden-Spatz disease using MRI, (123)I-beta-CIT-SPECT and (123)I-IBZM-SPECT.
Topics: Adolescent; Benzamides; Child; Cocaine; Globus Pallidus; Humans; Iodine Radioisotopes; Magnetic Resonance Imaging; Neurologic Examination; Pantothenate Kinase-Associated Neurodegeneration; Pyrrolidines; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon | 2000 |
[Hallervorden-Spatz disease: findings in the nigrostriatal system].
Topics: Adolescent; Benzamides; Cocaine; Corpus Striatum; Diagnosis, Differential; Disease Progression; Dopamine Antagonists; Humans; Iodine Radioisotopes; Magnetic Resonance Imaging; Male; Pantothenate Kinase-Associated Neurodegeneration; Parkinsonian Disorders; Pyrrolidines; Substantia Nigra; Tomography, Emission-Computed, Single-Photon | 2000 |